Literature DB >> 27289406

Cardiopulmonary Exercise Testing in Heart Failure.

Rajeev Malhotra1, Kristian Bakken2, Emilia D'Elia3, Gregory D Lewis4.   

Abstract

Exercise intolerance, indicated by dyspnea and fatigue during exertion, is a cardinal manifestation of heart failure (HF). Cardiopulmonary exercise testing (CPET) precisely defines maximum exercise capacity through measurement of peak oxygen uptake (VO2). Peak VO2 values have a critical role in informing patient selection for advanced HF interventions such as heart transplantation and ventricular assist devices. Oxygen uptake and ventilatory patterns obtained during the submaximal portion of CPET are also valuable to recognize because of their ease of ascertainment during low-level exercise, relevance to ability to perform activities of daily living, independence from volitional effort, and strong relationship to prognosis in HF. The ability of peak VO2 and other CPET variables to be measured reproducibly and to accurately reflect HF severity is increasingly recognized and endorsed by scientific statements. Integration of CPET with invasive hemodynamic monitoring and cardiac imaging during exercise provides comprehensive characterization of multisystem reserve capacity that can inform prognosis and the need for cardiac interventions. Here, we review both practical aspects of conducting CPETs in patients with HF for clinical and research purposes as well as interpretation of gas exchange patterns across the spectrum of preclinical HF to advanced HF.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiopulmonary exercise testing; exercise physiology; heart failure; oxygen uptake; ventilatory efficiency

Mesh:

Year:  2016        PMID: 27289406     DOI: 10.1016/j.jchf.2016.03.022

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  76 in total

1.  Wearable Patch-Based Estimation of Oxygen Uptake and Assessment of Clinical Status during Cardiopulmonary Exercise Testing in Patients With Heart Failure.

Authors:  Md Mobashir Hasan Shandhi; Sinan Hersek; Joanna Fan; Erica Sander; Teresa De Marco; J Alex Heller; Mozziyar Etemadi; Liviu Klein; Omer T Inan
Journal:  J Card Fail       Date:  2020-05-27       Impact factor: 5.712

2.  The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019.

Authors:  Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia
Journal:  Arq Bras Cardiol       Date:  2019-03       Impact factor: 2.000

3.  Prognostic value of VE/VCO2 slope in overweight heart failure patients.

Authors:  António Valentim Goncalves; Tiago Pereira-da-Silva; Rui Soares; Joana Feliciano; Ana Abreu; Pedro Rio; Rita Ilhao Moreira; Rui Cruz Ferreira
Journal:  Am J Cardiovasc Dis       Date:  2020-12-15

4.  Cardiopulmonary Exercise Testing-A Valuable Tool, Not Gatekeeper When Referring Patients With Adult Congenital Heart Disease for Transplant Evaluation.

Authors:  Jonathan N Menachem; Nosheen Reza; Jeremy A Mazurek; Danielle Burstein; Edo Y Birati; Arieh Fox; Yuli Y Kim; Maria Molina; Sara L Partington; Monique Tanna; Lynda Tobin; Joyce Wald; Lee R Goldberg
Journal:  World J Pediatr Congenit Heart Surg       Date:  2019-03-04

5.  Network Analysis to Risk Stratify Patients With Exercise Intolerance.

Authors:  William M Oldham; Rudolf K F Oliveira; Rui-Sheng Wang; Alexander R Opotowsky; David M Rubins; Jon Hainer; Bradley M Wertheim; George A Alba; Gaurav Choudhary; Adrienn Tornyos; Calum A MacRae; Joseph Loscalzo; Jane A Leopold; Aaron B Waxman; Horst Olschewski; Gabor Kovacs; David M Systrom; Bradley A Maron
Journal:  Circ Res       Date:  2018-02-05       Impact factor: 17.367

Review 6.  Performance and Interpretation of Invasive Hemodynamic Exercise Testing.

Authors:  C Charles Jain; Barry A Borlaug
Journal:  Chest       Date:  2020-05-28       Impact factor: 9.410

7.  Post-Exercise Oxygen Uptake Recovery Delay: A Novel Index of Impaired Cardiac Reserve Capacity in Heart Failure.

Authors:  Cole S Bailey; Luke T Wooster; Mary Buswell; Sarvagna Patel; Paul P Pappagianopoulos; Kristian Bakken; Casey White; Melissa Tanguay; Jasmine B Blodgett; Aaron L Baggish; Rajeev Malhotra; Gregory D Lewis
Journal:  JACC Heart Fail       Date:  2018-03-07       Impact factor: 12.035

8.  Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug
Journal:  JACC Heart Fail       Date:  2018-05-23       Impact factor: 12.035

9.  Left atrial mechanics strongly predict functional capacity assessed by cardiopulmonary exercise testing in subjects without structural heart disease.

Authors:  Luís Leite; Sofia Lázaro Mendes; Rui Baptista; Rogério Teixeira; Manuel Oliveira-Santos; Nelson Ribeiro; Rosa Coutinho; Victor Monteiro; Rui Martins; Graça Castro; Maria João Ferreira; Mariano Pego
Journal:  Int J Cardiovasc Imaging       Date:  2016-12-24       Impact factor: 2.357

10.  Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients.

Authors:  Simone Bartolini; Samuele Baldasseroni; Francesco Fattirolli; Maria Vittoria Silverii; Lucrezia Piccioli; Federico Perfetto; Niccolò Marchionni; Carlo Di Mario; Raffaele Martone; Giulia Taborchi; Sofia Morini; Elisa Vignini; Francesco Cappelli
Journal:  Intern Emerg Med       Date:  2020-09-12       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.